Terms: = Pancreatic cancer AND MEN1, ENSG00000133895, 4221 AND Clinical Outcome
8 results:
1. Thymidylate synthase accelerates men1-mediated pancreatic tumor progression and reduces survival.
Vijayakurup V; Maeng K; Lee HS; Meyer B; Burkett S; Nawab A; Dougherty MW; Jobin C; Mahmud I; Garrett TJ; Feely M; Lee KB; Kaye FJ; Guijarro MV; Zajac-Kaye M
JCI Insight; 2022 Oct; 7(19):. PubMed ID: 36048542
[TBL] [Abstract] [Full Text] [Related]
2. Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors.
Altieri B; Barrea L; Modica R; Bottiglieri F; de Cicco F; Muscogiuri G; Circelli L; Savarese G; Di Somma C; Savastano S; Colao A; Faggiano A
Endocrine; 2022 Feb; 75(2):623-634. PubMed ID: 34533768
[TBL] [Abstract] [Full Text] [Related]
3. ATRX, DAXX or men1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup.
Chan CS; Laddha SV; Lewis PW; Koletsky MS; Robzyk K; Da Silva E; Torres PJ; Untch BR; Li J; Bose P; Chan TA; Klimstra DS; Allis CD; Tang LH
Nat Commun; 2018 Oct; 9(1):4158. PubMed ID: 30315258
[TBL] [Abstract] [Full Text] [Related]
4. Long-term Follow-up of men1 Patients Who Do Not Have Initial Surgery for Small ≤2 cm Nonfunctioning pancreatic Neuroendocrine Tumors, an AFCE and GTE Study: Association Francophone de Chirurgie Endocrinienne & Groupe d'Etude des Tumeurs Endocrines.
Triponez F; Sadowski SM; Pattou F; Cardot-Bauters C; Mirallié E; Le Bras M; Sebag F; Niccoli P; Deguelte S; Cadiot G; Poncet G; Lifante JC; Borson-Chazot F; Chaffanjon P; Chabre O; Menegaux F; Baudin E; Ruszniewski P; Du Boullay H; Goudet P
Ann Surg; 2018 Jul; 268(1):158-164. PubMed ID: 28263205
[TBL] [Abstract] [Full Text] [Related]
5. pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future.
Ohmoto A; Rokutan H; Yachida S
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28098761
[TBL] [Abstract] [Full Text] [Related]
6. PTCH 1 staining of pancreatic neuroendocrine tumor (PNET) samples from patients with and without multiple endocrine neoplasia (MEN-1) syndrome reveals a potential therapeutic target.
Gurung B; Hua X; Runske M; Bennett B; LiVolsi V; Roses R; Fraker DA; Metz DC
Cancer Biol Ther; 2015; 16(2):219-24. PubMed ID: 25482929
[TBL] [Abstract] [Full Text] [Related]
7. Multiple endocrine neoplasia type 1 (men1): its manifestations and effect of genetic screening on clinical outcome.
Pieterman CR; Schreinemakers JM; Koppeschaar HP; Vriens MR; Rinkes IH; Zonnenberg BA; van der Luijt RB; Valk GD
Clin Endocrinol (Oxf); 2009 Apr; 70(4):575-81. PubMed ID: 18616711
[TBL] [Abstract] [Full Text] [Related]
8. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1.
Kouvaraki MA; Shapiro SE; Cote GJ; Lee JE; Yao JC; Waguespack SG; Gagel RF; Evans DB; Perrier ND
World J Surg; 2006 May; 30(5):643-53. PubMed ID: 16680581
[TBL] [Abstract] [Full Text] [Related]
